With New Phase 3 Data From Its Hemophilia Study, Novo Nordisk Plots Route To FDA
Novo Nordisk A/S (NYSE:NVO) announced the phase 3 results of the explorer7 study, assessing the efficacy and safety of prophylactic treatment…
Novo Nordisk’s Mim8 Shows Potential As Once Monthly Treatment For Hemophilia A
Novo Nordisk A/S (NYSE:NVO) announced that the phase 1 & 2 FRONTIER1 dose-escalation study in treating people with hemophilia…
MediWound Posts Early Data From Non-Melanoma Skin Cancer Trial
MediWound Ltd (NASDAQ:MDWD) announced initial data from eleven patients in its ongoing open-label Phase 1/2 study of MW005 for low-risk Basal…
Perrigo Seeks FDA Approval For the First OTC Contraceptive Pill
Perrigo Company plc's (NYSE: PRGO) HRA Pharma has
ViaCyte Acquisition Can Accelerate Vertex’s Ongoing Type 1 Diabetes Programs
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has agreed to acquire ViaCyte, a privately held biotechnology, for $320 million in cash. ViaCyte is focused…
Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase…
FDA Signs Off Nyxoah’s Genio Trial In Complete Concentric Collapse Patients
The FDA has approved Nyxoah SA’s (NASDAQ:NYXH) Investigational Device Exemption (IDE) to initiate a trial, called ACCCESS, to evaluate the Genio…
President Biden Mulls Health Emergency For Abortion Access: Report
U.S. President Joe Biden said he had asked his administration to consider whether he has the authority to…
Why Are Pliant Therapeutics Shares Rallying Today?
Pliant Therapeutics Inc’s (NASDAQ:PLRX) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and…
Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal
Innoviva Inc (NASDAQ:INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $5.95 per share, representing a premium of approximately 70%…